Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-Dimensional-Internal Dosimetry (3D-ID) software

George Sgouros, Katherine S. Kolbert, Arif Sheikh, Keith S. Pentlow, Edward F. Mun, Axel Barth, Richard J. Robbins, Steven M. Larson

Research output: Contribution to journalArticlepeer-review

269 Scopus citations


Compared with conventional, whole-organ, S-factor-based dosimetry, 3-dimensional (3D), patient-specific dosimetry better accounts for radionuclide distribution and anatomic patient variability. Its accuracy, however, is limited by the quality of the cumulated activity information that is provided as input. This input has typically been obtained from SPECT and planar imaging studies. The objective was to implement and evaluate PET-based, patient-specific, 3D dosimetry for thyroid cancer patients. Methods: Three to 4 PET imaging studies were obtained over a 7-d period in 15 patients with metastatic thyroid carcinoma after administration of 124I-NaI. Subsequently, patients were treated with 131I on the basis of established clinical parameters. Retrospective dosimetry was performed using registered 124I PET images that were corrected for the half-life difference between 124I and 131I. A voxel-by-voxel integration, over time, of the resulting 131I-equivalent PET-derived images was performed to provide a single 3D dataset representing the spatial distribution of cumulated activity values for each patient. Image manipulation and registration were performed using Multiple Image Analysis Utility (MIAU), a software package developed previously. The software package, 3D-Internal Dosimetry (3D-ID), was used to obtain absorbed dose maps from the cumulated activity image sets. Results: Spatial distributions of absorbed dose, isodose contours, dose-volume histograms (DVHs), and mean absorbed dose estimates were obtained for a total of 56 tumors. Mean absorbed dose values for individual tumors ranged from 1.2 to 540 Gy. The absorbed dose distribution within individual tumors was widely distributed ranging from a minimum of 0.3 to a maximum of 4,000 Gy. Conclusion: 124I PET-based, patient-specific 3D dosimetry is feasible, and sequential PET can be used to obtain cumulated activity images for 3D dosimetry.

Original languageEnglish (US)
Pages (from-to)1366-1372
Number of pages7
JournalJournal of Nuclear Medicine
Issue number8
StatePublished - Aug 1 2004


  • 3D-internal dosimetry
  • I
  • Patient-specific dosimetry
  • PET
  • Thyroid cancer

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology


Dive into the research topics of 'Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-Dimensional-Internal Dosimetry (3D-ID) software'. Together they form a unique fingerprint.

Cite this